Paper Details

  1. Home
  2. Paper Details

Effect of partial agonist activity on the side effects of beta-blockade in patients with chronic stable angina.

Author: AdamG, AkhrasF, ChambersJ, JacksonG, OngM L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Epanolol, a beta 1-partial agonist, is as effective as atenolol for chronic stable angina and may improve the side effect profile in some patients.
Paper Details　
Original Abstract of the Article :
Some side effects of the beta 1-adrenoceptor blocker atenolol may result from depression of cardiac output at rest. They may, therefore, be reduced by the use of drugs with beta 1-partial agonist activity, such as epanolol. We compared once-daily atenolol 100mg and epanolol 200mg in 20 patients repo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00003495-198900382-00009

データ提供：米国国立医学図書館（NLM）

Exploring Partial Agonist Activity in Beta-Blockers for Chronic Stable Angina

This study investigates the therapeutic landscape of beta-blockers, commonly used to manage chronic stable angina. The authors delve into the potential benefits of partial agonist activity in beta-blockers, specifically comparing atenolol, a full beta-blocker, with epanolol, a partial agonist. The study aims to assess the impact of partial agonist activity on the side effects associated with beta-blockade while maintaining antianginal efficacy.

Balancing Benefits and Side Effects in Angina Treatment

The study underscores the importance of understanding the nuances of beta-blocker therapy. While full beta-blockers like atenolol are effective in managing angina, they can sometimes cause side effects due to their complete blockade of beta-receptors. This study explores the potential of partial agonists like epanolol to reduce these side effects while maintaining therapeutic efficacy.

Optimizing Treatment for Chronic Stable Angina

The study suggests that partial agonists like epanolol may offer a more balanced approach to managing chronic stable angina. While demonstrating similar antianginal efficacy to full beta-blockers, epanolol was associated with fewer side effects, particularly in patients who experienced discomfort with full beta-blockers. This research encourages further exploration of partial agonists as a promising option for managing chronic stable angina.

Dr.Camel's Conclusion

Imagine the treatment of chronic stable angina as a journey across a desert landscape, with full beta-blockers acting as a sturdy camel, capable of carrying a heavy load but sometimes prone to fatigue. Partial agonists like epanolol, like a nimble Arabian horse, offer a more balanced approach, navigating the terrain with agility and grace, minimizing the strain on the traveler. This study highlights the potential of partial agonists as a valuable option for navigating the challenges of chronic stable angina.

Date :
  1. Date Completed 1990-03-19
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

2575979

DOI: Digital Object Identifier

10.2165/00003495-198900382-00009

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.